Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience.
Sara CacciapuotiLuca PotestioGallo LuciaMusumeci Maria LetiziaGiacomo CaldarolaDomenico D'AmicoCaudullo FrancescoPapaianni ValeriaClara De SimoneKetty PerisMatteo MegnaPublished in: International journal of dermatology (2024)
Tildrakizumab is a valuable option for treating difficult-to-treat psoriasis and pruritus, with rapid onset of action.